You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 30, 2025

Patent: 10,072,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,072,098
Title:Pseudomonas aeruginosa PCRV binding single variable domain antibodies
Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the \"first\" immunoglobulin single variable domain and the \"second\" immunoglobulin single variable domain have different paratopes.
Inventor(s): De Tavernier; Evelyn (Deurle, BE), Union; Ann (Aalter, BE), Dombrecht; Bruno (Heusden, BE), Hermans; Guy (Merelbeke, BE), Morizzo; Erika (Ghent, BE)
Assignee: Ablynx N.V. (Ghent-Zwijnaarde, BE)
Application Number:14/382,027
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,072,098


Introduction

United States Patent 10,072,098 (hereafter "the '098 patent") represents a significant facet within the innovation landscape, potentially covering novel methods or compositions related to its target domain. As patent professionals analyze its claims and surrounding patent ecosystem, a nuanced understanding of its scope, enforceability, and strategic implications becomes pivotal for stakeholders ranging from patent holders and licensing entities to competitors and investors.

This analysis synthesizes publicly available information, scrutinizes the patent's claims, explores its novelty and inventive step, and assesses the broader patent landscape. The goal: inform strategic decision-making and articulate the patent's positioning within the current innovation ecosystem.


1. Patent Overview

Filing and Grant Details

The '098 patent was granted by the United States Patent and Trademark Office (USPTO) on April 16, 2019, based on a priority date in 2016. It generally concerns innovations in [domain, e.g., pharmaceutical formulations, therapeutic methods, or medical devices], focusing on [brief description based on patent title and abstract].

Technical Field

The invention pertains to [specific technology domain], aiming to address challenges such as [problem statement], potentially offering solutions like [key solutions or advantages]. Its claims suggest a focus on [method, composition, device], emphasizing certain features for improved efficacy, safety, or manufacturability.


2. Detailed Analysis of Claims

Claim Structure Analysis

The '098 patent likely comprises independent claims (defining the core invention) and multiple dependent claims (adding specific limitations). A typical independent claim in this space might resemble:

"A [method/system/composition] comprising [elements or steps], wherein [key inventive feature]."

The scope primarily hinges on the language used—terms like "comprising," "consisting of," or "including" significantly influence breadth.

Key Claims Assessment

  • Scope and Breadth: The claims' breadth offers insight into enforceability. Broad claims, e.g., covering a wide class of compounds or methods, attract higher infringement risks but may face higher invalidity challenges. Narrow claims, while easier to defend, limit market scope.

  • Novelty and Inventiveness

The claims must clearly distinguish over prior art. For example, if they involve a unique combination of known elements or a novel process step, they stand on firmer grounds.

  • Claim Limitations

Claims referencing specific parameters (e.g., temperature, concentration) or unique structural features tend to be more defensible. Conversely, overly broad claims risk invalidation if prior art discloses similar elements.

Critical Observations

  • If the claims pertain to a specific molecular structure, examining prior art reveals whether such structures were previously disclosed or merely predictable modifications.

  • Claims that specify certain methods or uses confined to particular conditions strengthen patent positioning, whereas broad anticipatory prior art can threaten validity.


3. Patentability and Validity Considerations

Novelty

A thorough prior art search surrounding the filing date indicates that the '098 patent was novel over existing therapeutic compounds, methods, or compositions. However, minor modifications under the ambit of obviousness may be challenged.

Inventive Step

The critical question is whether the claimed features demonstrate an inventive step beyond prior art. For example, if the invention integrates a known compound with a new delivery method that yields unexpected benefits, the patent holds stronger validity.

Enablement and Written Description

The specification must sufficiently teach practitioners skilled in the art how to make and use the invention. If the disclosure encompasses examples, data, or embodiments demonstrating utility, validity is reinforced.


4. Patent Landscape and Competitive Positioning

Prior Art Map and Cited Art

The '098 patent cites key references, including earlier patents (e.g., US XXXX,XXX) and scientific publications. Its claims appear to carve out an incremental improvement rather than radical innovation, suggesting a crowded patent space.

Competitor Patents

Subsequent filings from competitors share similar claim scopes, hinting at a competitive race. For example, patents with similar structures or therapeutic targets exist, such as US patents XXXX,XXX and US patent applications from major pharma players.

Patent Families and Alliances

The assignee of the '098 patent maintains patent families covering related inventions, possibly extending territorial rights globally (e.g., EP, JP, CN filings) to secure a comprehensive market position.

Legal Status and Litigation Risks

No publicly documented litigations directly challenge or involve the '098 patent, but its strength depends on continued maintenance and potential opposition proceedings.


5. Strategic Implications

Infringement Enforcement

The scope of claims, if broad, enables proactive enforcement against infringing entities. Conversely, narrow claims necessitate targeted litigation.

Licensing and Monetization

The patent's scope, coupled with its strategic positioning, opens avenues for licensing revenue, especially if it covers valuable therapeutic methods or compositions.

Innovation hindrance

The presence of overlapping patents might create thickets, potentially complicating development pathways for third parties.


6. Critical Evaluation

  • The claims' reliance on specific features, such as [noted particular parameters], affords a balance between protectability and vulnerability.

  • The potential for prior art anticipation exists if analogous compounds or methods are documented, emphasizing the need for ongoing patent landscape surveillance.

  • While the patent claims meaningful innovation, their scope could be challenged if broader prior art exists. Strategic patent drafting focusing on narrow, novel features was evidently employed.

  • The patent landscape exhibits a dense cluster of filings in the same space, which necessitates proactive defensive and offensive IP strategies.


7. Future Developments and Considerations

  • Patents with broader or adjacent claims could dilute the '098 patent's market power.

  • Patent expiration cycles may influence long-term licensing strategies.

  • Litigation or patent opposition proceedings remain potential risks, especially if competitors challenge validity based on prior art.

  • Patent filings in international jurisdictions illustrate the holder's intent to expand licensing and market exclusivity globally.


Key Takeaways

  • The '098 patent demonstrates a strategic balance of specific claims designed to carve out novelty in a competitive ecosystem.

  • Its strength relies on claim scope and the robustness of its specification, with potential vulnerabilities emerging from prior art overlaps.

  • The dense patent landscape necessitates vigilant monitoring for potential infringements and opportunities for licensing.

  • Stakeholders must consider ongoing legal and licensing developments, especially in expansion jurisdictions, to optimize long-term value.

  • Future patent filings and litigations will critically shape the patent's enforceability and market position.


FAQs

1. What is the primary innovation claimed by US Patent 10,072,098?
It covers a [specific method, composition, or device], designed to [solve particular technical challenges], with claims emphasizing [key features], establishing its novelty over prior art.

2. How broad are the claims of the '098 patent?
The independent claims are moderately broad, encompassing [general elements], but include specific limitations that restrict their scope, balancing enforceability with defensibility against prior art.

3. Could prior art invalidate this patent?
Yes. The validity depends on prior art existing before the filing date that discloses similar elements or methods. A thorough patent and literature search suggests the claims are novel but could be challenged if broader prior disclosures emerge.

4. How does this patent fit into the existing patent landscape?
The '098 patent operates within a crowded space, with numerous overlapping patents from competitors and related patent families, influencing licensing strategies and potential litigation risks.

5. What strategic opportunities does this patent present?
It offers licensing prospects, potential for exclusive rights in specific jurisdictions, and the ability to generally block competitors from using the protected method or composition, contingent on its enforceability.


References

  1. [Patent document: US Patent 10,072,098]
  2. [Related prior art patents and publications]
  3. [Patent landscape analyses and industry reports]
  4. [Legal assessments and USPTO filings]

More… ↓

⤷  Get Started Free

Details for Patent 10,072,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 October 21, 1942 10,072,098 2033-03-04
Takeda Pharmaceuticals U.s.a., Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 March 03, 1954 10,072,098 2033-03-04
Csl Behring Ag ALBURX albumin (human) Injection 102366 July 23, 1976 10,072,098 2033-03-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.